University of Missouri-Columbia
missouri.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
359
Active
76
Phase 3
8
Total enrollment
37,915
Pipeline matrix
Showing 33 of 33 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| saline 0.9% | — | — | — | — | — | 4 | |
| N-acetylcysteine | — | — | — | — | 2 | ||
| Hibiclens | — | — | — | — | — | 1 | |
| Isopropyl Alcohol 70% Topical Application Solution | — | — | — | — | — | 1 | |
| GLP-1 receptor agonist | — | — | — | — | — | 1 | |
| Saline | — | — | — | — | — | 1 | |
| Amoxicillin/clavulanate | — | — | — | — | — | 1 | |
| Ciprofloxacin | — | — | — | — | — | 1 | |
| Clindamycin | — | — | — | — | — | 1 | |
| Dexamethasone | — | — | — | — | — | 1 | |
| Methadone-dexmedetomidine-ketamine combination | — | — | — | — | — | 1 | |
| bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg | — | — | — | — | — | 1 | |
| Lactated Ringers | — | — | — | — | — | 1 | |
| Empagliflozin 10 MG | — | — | — | — | — | 1 | |
| Clavulanic Acid | — | — | — | — | — | 1 | |
| Sirolimus | — | — | — | — | — | 1 | |
| Norepinephrine | — | — | — | — | — | 3 | |
| Gemtesa | — | — | — | — | — | 2 | |
| Isoproterenol | — | — | — | — | — | 2 | |
| Propranolol Hydrochloride | — | — | — | — | — | 2 | |
| Phentolamine | — | — | — | — | — | 2 | |
| Propranolol | — | — | — | — | 5 | ||
| Human insulin | — | — | — | — | — | 2 | |
| Lidocaine Epinephrine | — | — | — | — | — | 1 | |
| Bupivacaine Hydrochloride-EPINEPHrine | — | — | — | — | — | 1 | |
| Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine | — | — | — | — | — | 1 | |
| Acetylcholine | — | — | — | — | — | 1 | |
| Nitroprusside | — | — | — | — | — | 1 | |
| Estrogen | — | — | — | — | — | 1 | |
| Phentolamine Mesylate | — | — | — | — | — | 1 | |
| Phenylephrine | — | — | — | — | — | 1 | |
| Dexmedetomidine | — | — | — | — | 2 | ||
| Whole Genome Sequencing | — | — | — | — | — | 1 |
Next readouts
- 2024-06-06
- 2025-09-19
- 2026-05-01
- 2026-06
- 2026-06-30
- 2026-06-30
- 2026-07
- 2026-08-31
- 2026-12
- 2026-12
Top conditions
- Obesity23
- Healthy13
- Insulin Resistance10
- Insomnia10
- Metabolic Syndrome8
- Aging8
- Type 2 Diabetes7
- Vasodilation6
Frequently asked questions about University of Missouri-Columbia
- How many clinical trials does University of Missouri-Columbia have on ClinicalTrials.gov?
- University of Missouri-Columbia is listed as the lead sponsor on 359 clinical trials in ClinicalTrials.gov, 76 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Missouri-Columbia's trials are in Phase 3?
- 8 of University of Missouri-Columbia's trials are in Phase 3, spread across 33 active drug programs.
- What therapeutic areas does University of Missouri-Columbia focus on?
- University of Missouri-Columbia's most-studied conditions on ClinicalTrials.gov are Obesity, Healthy, Insulin Resistance, Insomnia, Metabolic Syndrome.
- When are University of Missouri-Columbia's next clinical trial readouts?
- University of Missouri-Columbia has 10 upcoming primary-completion readouts tracked here; the soonest is “Exparel Injection Effect on Postoperative Opioid Usage”, expected around 2024-06-06.